Yissum Technology Transfer Company of the Hebrew University
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. is a technology transfer company established in 1964 that focuses on protecting and commercializing the intellectual properties of the Hebrew University. It markets and licenses innovations developed by the university's faculty, staff, and students across diverse fields such as agriculture, life sciences, nanotechnology, and environmental technologies. Yissum has a strong track record, having registered over 10,000 patents and produced more than 130 spin-off companies, including notable names like Mobileye and Collplant. The company engages in strategic collaborations with various global partners and manages several venture capital funds, including those targeting nanotechnology, cleantech, and agro-biotechnology. Yissum is headquartered in Jerusalem and has international cooperation centers in Chicago, Asunción, and Shenzhen.
Agrinnovate India
Series A in 2015
Agrinnovate India Ltd., established on October 19, 2011, under the Companies Act, 1956, is a profit-oriented company owned by the Department of Agricultural Research & Education, Ministry of Agriculture, Government of India. Its primary role is to serve as a conduit between the Indian Council of Agricultural Research and various stakeholders in the agricultural sector, including farmers, public and private firms, research and development organizations, and educational institutions, both nationally and internationally. Agrinnovate India focuses on promoting agricultural research and development outcomes, emphasizing the protection of intellectual property rights. By fostering innovation and enhancing agricultural development through strategic partnerships, the company aims to contribute significantly to global agricultural progress.
Avraham Pharmaceuticals
Venture Round in 2014
Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, established in 2010. The company focuses on developing innovative treatments for neurodegenerative disorders. Its lead product candidate, Ladostigil, is aimed at addressing mild cognitive impairment and is designed to incorporate neuroprotective mechanisms, including the reduction of oxidative stress and microglial activation, as well as the inhibition of pro-inflammatory cytokines. Avraham Pharmaceuticals has raised $9 million to support a European Phase II proof-of-concept efficacy trial for Ladostigil in patients with Alzheimer's disease.
Avraham Pharmaceuticals
Private Equity Round in 2013
Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, established in 2010. The company focuses on developing innovative treatments for neurodegenerative disorders. Its lead product candidate, Ladostigil, is aimed at addressing mild cognitive impairment and is designed to incorporate neuroprotective mechanisms, including the reduction of oxidative stress and microglial activation, as well as the inhibition of pro-inflammatory cytokines. Avraham Pharmaceuticals has raised $9 million to support a European Phase II proof-of-concept efficacy trial for Ladostigil in patients with Alzheimer's disease.
Avraham Pharmaceuticals
Venture Round in 2011
Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, established in 2010. The company focuses on developing innovative treatments for neurodegenerative disorders. Its lead product candidate, Ladostigil, is aimed at addressing mild cognitive impairment and is designed to incorporate neuroprotective mechanisms, including the reduction of oxidative stress and microglial activation, as well as the inhibition of pro-inflammatory cytokines. Avraham Pharmaceuticals has raised $9 million to support a European Phase II proof-of-concept efficacy trial for Ladostigil in patients with Alzheimer's disease.
Avraham Pharmaceuticals
Series A in 2010
Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, established in 2010. The company focuses on developing innovative treatments for neurodegenerative disorders. Its lead product candidate, Ladostigil, is aimed at addressing mild cognitive impairment and is designed to incorporate neuroprotective mechanisms, including the reduction of oxidative stress and microglial activation, as well as the inhibition of pro-inflammatory cytokines. Avraham Pharmaceuticals has raised $9 million to support a European Phase II proof-of-concept efficacy trial for Ladostigil in patients with Alzheimer's disease.
Chiasma, Inc. is a late-stage biopharmaceutical company based in Needham, Massachusetts, that specializes in developing oral medications for rare and serious chronic diseases. Utilizing its proprietary Transient Permeability Enhancer technology, Chiasma aims to transform injectable drugs into oral formulations, enhancing their absorption and potentially enabling new therapeutic indications. The company is currently focused on MYCAPSSA, an oral octreotide capsule designed for adult patients with acromegaly, a condition characterized by excessive growth hormone production. MYCAPSSA is undergoing Phase III clinical trials in the United States and is also in the process of seeking regulatory approval in the European Union. Founded in 2001, Chiasma is dedicated to improving treatment options for patients with debilitating conditions through innovative drug delivery methods.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.